MOSAIC HUMAN PREIMPLANTATION EMBRYOS AND THEIR DEVELOPMENTAL POTENTIAL IN A PROSPECTIVE NON-SELECTION CLINICAL TRIAL

• Based in this clinical trial and according with emerging evidence, embryos with copy number variations between 30-50% (low mosaic grade) have equal reproductive potential as embryos with copy number variations less than 30% (reported as euploid).
• Concordance studies have shown that biopsies with a low mosaic result most likely have euploid inner cell mas (ICM), the part of the embryo that will become the fetus.
• The recently published PGDIS Position Statement on the transfer of low mosaic embryos states that these embryos should not be disregarded in terms of suitability for transfer.
• This is the only non-selection study published based on its own internal validation of PGT-A using NGS, showing the potential outcome of transferring <50% mosaic embryos.

Learn More Download Clinical Sheet

CHECK OUT OUR LATEST ENDOMETRIO PUBLICATIONS

In the past weeks, 2 new independent peer reviewed studies have been published about the ERA test.​

Only ERA, developed and patented by Igenomix in 2009 is backed by dozens of internal and external peer-reviewed publications.​
​
In fact, other endometrial tests in the market are using Igenomix publications to support their tests, when publications about ERA are unique and cannot be extrapolated to other endometrial tests.

• ERA in RIF patients levels their reproductive outcome to good prognosis patients. Liu et al. Front Physiol, 2022. READ PAPER
• RIF patients who had a personalized embryo transfer according to ERA had a significatively better reproductive outcome. Jia et al. Medical Science Monitor, 2022. READ PAPER
• Endometrial microbiota composition is associated with reproductive outcome in infertile patients. Moreno et al. Microbiome Journal, 2022. READ PAPER

ENDOMETRIO IS A COMPLETE ANALYSIS OF ENDOMETRIAL HEALTH, INCLUDING THE ERA, EMMA AND ALICE TESTS

• Evaluates endometrial receptivity and determines the optimal moment for embryo transfer.
• Analyzes the endometrial microbiome for a more favorable reproductive prognosis.
• Detects bacteria that cause Chronic Endometritis and recommends the proper treatment.

Download Clinical Sheet

NON-INVASIVE PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDIES: AN UPDATE

• Aneuploidy is common among preimplantation human embryos used in assisted reproductive technology. Because abnormal chromosome number can negatively affect outcomes, in vitro-fertilized embryos routinely undergo aneuploidy testing before transfer into the uterus. This testing typically involves an invasive trophectoderm biopsy of a blastocyst-stage embryo. However, emerging evidence indicates that, during in-vitro development, embryos secrete cell-free DNA into their culture medium; this phenomenon suggests the potential for an alternative, non-invasive assay for aneuploidy.
• We recently published an exhaustive update of non-invasive preimplantation genetic testing for aneuploidies in which we summarize all studies published so far on the topic, the main focus of the review is on the practical aspects of this new and promising technique.

• Can different embryo culture protocols be applied?
• Is assisted hatching or previous vitrification needed?
• How can contamination be minimized?
• How long should the medium be in contact with the embryo before its collection?

• These questions and much more will be answered in this review. Are you going to miss it?

Learn More Download Clinical Sheet

ZENIT IS AN ADVANCED NON-INVASIVE TEST THAT OFFERS A NEW DIMENSION IN PRENATAL SCREENING

• 3-4%* of all babies are born with some type of genetic disorder
• Zenit offers the widest coverage of pregnancy risk classification.
• In addition to analysing the risk of chromosomal abnormalities in the foetus, Zenit studies 113 pathogenic monogenic disorders.
• Zenit is indicated for all women who want to have a complete understanding of pregnancy risk as possible. 

Download Clinical Sheet

• Newborn screening is a mandatory public health program that offers screening and follow-up medical care to all newborns for a variety of medical conditions.
• Igenomix Newborn Screening Test is a comprehensive genetic test that analyzes 237 genes using Next Generation Sequencing (NGS) technologies allowing a direct approach of genetic disorders to reach a rapid, accurate diagnosis.
• In addition, this test identifies if a child is a healthy carrier of any of these genetic alterations.

The goals of newborn screening are:

• Decrease morbidity and mortality of actionable diseases by performing an early intervention to improve neonatal and long-term health outcomes.
• Provide a universal health service of screening to all newborns.
• Identifying screen-positive newborns
• Diagnosing conditions
• Communication with families
• Referral to treatment centers
• Follow up with long-term outcomes
• Educating physicians and patients.

Download Clinical Sheet

• One online channel to operate and communicate with Igenomix.
• Easy to access your patient reports anytime.
• Live Chat with Igenomix Customer Support.
• Follow up your patient report easily and faster.

Our clinic portal allows you to:

• • Test Ordering
  • Report Download
  • Kit request
  • Clinical Data
  • Educational Content
  • Online Live Chat